Last reviewed · How we verify
Pre-radiation temozolomide.
At a glance
| Generic name | Pre-radiation temozolomide. |
|---|---|
| Sponsor | The Cooper Health System |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma (PHASE1)
- Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors (EARLY_PHASE1)
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma (PHASE1)
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (PHASE1)
- DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma (PHASE1, PHASE2)
- PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PHASE1, PHASE2)
- Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. (PHASE2)
- Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pre-radiation temozolomide. CI brief — competitive landscape report
- Pre-radiation temozolomide. updates RSS · CI watch RSS
- The Cooper Health System portfolio CI